Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Zenas BioPharma, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Zenas BioPharma, Inc. (ZBIO) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zenas BioPharma, Inc. (“Zenas” or “the Company”) (NASDAQ: ZBIO). Investors who purchased Zenas securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Zenas has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On January 5, 2026, Zenas issued a press release announcing “results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD).” Although Zenas characterized the results as “positive,” analysts noted that the drug’s reported efficacy likely fell short of the relevant threshold for commercial viability. Following this news, Zenas’s stock price fell $17.89 per share, or 51.86%, to close at $16.61 per share on January 5, 2026.
What Should Zenas BioPharma, Inc. (ZBIO) Investors Do?
If you are aware of any facts relating to this investigation or purchased Zenas securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
How Is Zenas BioPharma, Inc. (NASDAQ: ZBIO) Stock Trading Today?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”